Skip to main content

Boston Scientific Value Stock - Dividend - Research Selection

Boston scientific

ISIN: US1011371077 , WKN: 884113

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson\'s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


KMTS, Biobeat Partner to Expand Diagnostic Insight in Cardiac Recovery

2026-01-14
Kestra teams up with Biobeat in an exclusive deal, investing $5M to add continuous blood pressure monitoring to the ASSURE WCD during cardiac recovery.

Reasons to Retain TransMedics Stock in Your Portfolio for Now

2026-01-14
TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.

Baxter Unveils Dynamo Smart Stretcher to Improve Hospital Safety

2026-01-14
BAX introduces its Dynamo Series smart stretcher, aiming to boost hospital safety and reduce patient transfers.

The Zacks Analyst Blog Highlights AngioDynamics, Boston Scientific and Medtronic

2026-01-14
AngioDynamics shows how product mix shifts toward higher-margin Med Tech platforms are quietly reshaping earnings power across medtech stocks.

Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?

2026-01-14
EW benefits from strong TAVR and TMTT momentum, but macro pressures and FX headwinds cloud the near-term outlook.

Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?

2026-01-14
TMO ramps up acquisitions and product launches to drive growth, but heavy debt and currency headwinds raise questions for long-term holders.

Pulling back 3.7% this week, Boston Scientific's NYSE:BSX) five-year decline in earnings may be coming into investors focus

2026-01-14
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

JPM26: Boston Scientific expects strong PFA performance for 2026 and beyond

2026-01-14
Boston Scientific expects incredibly high growth for its pulsed field ablation (PFA) devices, driven by increased usage of its existing catheters.

3 MedTech Stocks Benefiting From Favorable Product Mix Shifts

2026-01-13
ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.

JPM26: Boston Scientific strengthens urology portfolio with Valencia Technologies acquisition

2026-01-13
Valencia’s eCoin implantable tibial nerve stimulation (ITNS) system for urge urinary incontinence (UUI) treatment gained FDA approval in 2022.